Last reviewed · How we verify
NCT05116995: DEFINE CCS
Differential EFfects of Dual antIplatelet and Dual aNtithrombotic thErapy on Hemostasis in Chronic Coronary Syndrome Patients
Phase 4 trial testing Rivaroxaban in Thrombosis in 30 participants. Status unknown.
1 November 2023
Quick facts
| Lead sponsor | Nova Scotia Health Authority |
|---|---|
| Phase | Phase 4 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 1 November 2021 |
| Primary completion | 1 November 2023 |
| Estimated completion | 1 November 2023 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- Rivaroxaban (rivaroxaban) — full drug profile →
- Ticagrelor (ticagrelor) — full drug profile →
Conditions studied
- Thrombosis — all drugs for Thrombosis →
- Myocardial Infarction — all drugs for Myocardial Infarction →
Sponsor
Nova Scotia Health Authority — full company profile →
Who can join
55 and older, any sex, with Thrombosis or Myocardial Infarction. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The investigators will be comparing the effects of two different drug treatment strategies, in patients with history of a heart attack, on different markers of bleeding and clotting risk. Both treatment strategies are already approved for the indication of improving outcomes in high-risk patients with history of heart attack.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05116995
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Rivaroxaban
Trials testing the same drug.
- NCT06953726 — Comparing the Safety and Efficacy of Apixaban and Rivaroxaban · Phase 4 · not yet recruiting
- NCT07468448 — Combination Antithrombotic Treatment for Prevention of Recurrent Ischemic Stroke in IntraCranial Atherosclerotic diseaSe · Phase 3 · not yet recruiting
- NCT07318610 — Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Disease · Phase 3 · not yet recruiting
- NCT07312851 — A Study to Investigate Andexanet Dosing and the Interaction Between Andexanet and Subsequent Enoxaparin in Healthy Parti · Phase 1 · recruiting
- NCT06961630 — Post-Operative Biomarker-Guided Precision Medicine For Cardiovascular Risk Reduction · EARLY_PHASE1 · recruiting
Other recruiting trials for Thrombosis
Currently open trials in the same condition.
- NCT07137429 — Platelet Volunteers, Longitudinal and Multi-omic Study · recruiting
- NCT06676904 — Neonatal Platelet Transfusion Threshold Trial · NA · recruiting
- NCT06993740 — Effect of Dexmedetomidine on Microsurgery Reconstruction in Cancer Patient · NA · recruiting
- NCT07358416 — Complications and Antiplatelet and Anticoagulant Therapy in Vascular Surgery. · active not recruiting
- NCT06370273 — Thromboprophylaxis in Lower Limb Immobilisation · Phase 3 · recruiting
Other Nova Scotia Health Authority trials
Trials by the same sponsor.
- NCT03716999 — Starlight Therapy in Palliative Care · not yet recruiting
- NCT06987409 — Continuous Erector Spinae Block for Analgesia Following Lumbar Decompression · NA · not yet recruiting
- NCT06575621 — Knee-hip Surgery Wait-list Support Program · NA · not yet recruiting
- NCT07143162 — YOGA-FIT: Protocol for a Crossover Trial Investigating the Feasibility and Impact of Yoga for People With Stroke · NA · not yet recruiting
- NCT07239999 — Comparing Spinal Anesthesia With 1% Chloroprocaine Versus 1% Mepivacaine in Patients Undergoing Outpatient Primary Total · Phase 4 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05116995 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Nova Scotia Health Authority
- Last refreshed: 22 September 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05116995.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing